|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-5-5
|
|
pubmed:abstractText |
Survivin is an attractive target for anti-cancer drug development; however targeting it by small molecules or antibodies is difficult, as survivin is neither a kinase nor a cell surface protein. Protein transduction domain (PTD)-mediated macromolecular therapeutics provides an alternative avenue for targeting survivin.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1423-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19414397-Apoptosis,
pubmed-meshheading:19414397-Blotting, Western,
pubmed-meshheading:19414397-Cell Proliferation,
pubmed-meshheading:19414397-Chromatography, Affinity,
pubmed-meshheading:19414397-Genes, Dominant,
pubmed-meshheading:19414397-Humans,
pubmed-meshheading:19414397-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:19414397-Lung Neoplasms,
pubmed-meshheading:19414397-Microtubule-Associated Proteins,
pubmed-meshheading:19414397-Recombinant Proteins,
pubmed-meshheading:19414397-Tumor Cells, Cultured
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Pro-apoptosis and anti-proliferation effects of a recombinant dominant-negative survivin-T34A in human cancer cells.
|
|
pubmed:affiliation |
Department of Nuclear Medicine, University of Ulm, Ulm, Germany. shenchangxian@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
